Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
One of the most important sectors in any country's economy is the biotech sector. Picking under-the-radar biotech stocks is easier said than done because we do not see immediate results....
With the technology sector taking over in 2024, now is a great time to consider the best breakout biotech stocks to buy. Investing in these companies can be risky yet extremely rewarding, with careful...
If you have some cash on hand to invest long term, there are plenty of stocks begging to be bought. Vertex expects several product launches even as its mainstay portfolio continues to drive profitabil...
The rare disease drug industry is fast-growing, while the music streaming space is also expanding at a rapid clip. Vertex is raking in profits from its cystic fibrosis drug franchise, but is also plan...
Vertex Pharmaceuticals could have multiple new blockbusters on the way. Viking Therapeutics is targeting two massive markets -- obesity and NASH....
A rare-disease drugmaker and a top pharmaceutical stock have what it takes to deliver solid returns over the long run. Vertex Pharmaceuticals' flagship business continues to expand market share and pr...
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year....
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
In the world of investing, biotech stocks represent a unique blend of high risk and high reward. After a period of volatility in the broader markets in 2022 and 2023, biotech stocks are now drawing at...
